Achievements

    • 1

      Dilip Shanghvi made notable international acquisitions. His biggest ventures took place with the America’s Caraco Pharma, and the Israel’s Taro Pharma. Later in 2014, he took over Ranbaxy and successfully made the Sun Pharmaceuticals, the largest pharma company in India. It gained global recognition as the fifth largest specialty generic company.

    • 2

      Dilip Shanghvi was bestowed with the honor of the Entrepreneur of the Year in 2010.

    • 3

      In 2011, he was presented with the ‘CNN-IBN Indian of the Year’ in the business category.

    • 4

      The Government of India awarded the Indian pharma man with the civilian honour of the Padma Shri in 2016.

Dilip Shanghvi owns a beautiful residence in Surat, Gujarat build by India Matharoo Associates.

Sun Pharmaceuticals was founded in 1983 and today the revenue has grown up to 22.37 Billion.

Possessions

    • 1

      Dilip Shanghvi owns a house in the suburbs of Juhu, where he lives with his family.

    • 2

      Dilip Shanghvi holds a wonderful project that is placed in Surat, Gujarat, built by the India Matharoo Associates, offering the residential wants with all lavishing facilities.

Interesting Facts

    • 1

      Dilip Shanghvi, the soft-spoken man and a real generous individual, started his pharma business with just five products and five people and has enrolled himself in the list of billionaires today. He even surpassed Mukesh Ambani as the richest person in India, in 2015.

    • 2

      Dilip Shanghvi’s success was also noticed in the industry when he decided to enter the niche markets like lifestyle and psychiatry drugs.

    • 3

      Dilip Shanghvi’s pharma is also the largest Indian pharma company in the US and the fifth largest specialty generic company globally.

    • 4

      Dilip Shanghvi also serves as the Chairman and the Managing Director of the Research Department in Sun Pharmaceutical Company. The Indian Stock Exchange enlisted it to be the first ever pure-R&D Company.

Dilip Shanghvi has acquired more than 16 companies including US-based Caraco Pharma, Israeli company Taro Pharma and Ranbaxy.